Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients with MSI-H or dMMR mCRC By Ogkologos - December 9, 2024 768 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma March 25, 2022 ¿Puede el uso de aceites esenciales ayudar a tratar el cáncer... June 23, 2022 Robust and Durable Clinical Activity of Tepotinib in Patients with METex14-Skipping... June 21, 2023 A Combination of Durvalumab-Tremelimumab with mFOLFOX6 Is Tolerable with Promising Activity... August 29, 2023 Load more HOT NEWS Adding Atezolizumab to Cabozantinib Fails to Improve Clinical Outcomes and Increases... Newly Developed RSClin Provides Prognostic Information in HR-positive, HER2-negative Early Breast... EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide PSMA PET-CT Accurately Detects Prostate Cancer Spread, Trial Shows
